加载中
NASDAQHealthcareBiotechnology
最新数据
US$2.10
US$0.00 · 0.00%
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
收盘时
US$2.10
US$0.00 · 0.00%
盘后
US$2.10
US$0.00 · 0.00%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
日内区间
当前US$2.10
52周区间
当前US$2.10
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
26
偏贵
情绪
52
多空交织
风险
83
极高风险
动量
31
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
日内区间
当前US$2.10
52周区间
当前US$2.10
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 10万 USD | 12万 USD | 12.7万 USD | 12.2万 USD | 12.1万 USD |
| 毛利 | −10万 USD | −12万 USD | −12.7万 USD | −12.2万 USD | −12.1万 USD |
| 研究与开发 | 73.1万 USD | 92.7万 USD | 107.1万 USD | 129万 USD | 155.9万 USD |
| 销售、一般及管理费用 | 177.6万 USD | 112.9万 USD | 172.6万 USD | 153.9万 USD | 84.5万 USD |
| 营业费用 | 250.7万 USD | 205.6万 USD | 279.7万 USD | 282.9万 USD | 240.4万 USD |
| 利息收入 | 61万 USD | 7000 USD | 5.6万 USD | 5000 USD | 6000 USD |
| 利息支出 | 253.9万 USD | 103.5万 USD | 75.7万 USD | 76.5万 USD | 83.5万 USD |
| 折旧和摊销 | 10万 USD | 12万 USD | 12.7万 USD | 12.3万 USD | 12.2万 USD |
| 营业利润 | −260.7万 USD | −205.6万 USD | −279.7万 USD | −282.9万 USD | −240.4万 USD |
| 净利润 | −467.1万 USD | −301.9万 USD | −440万 USD | −663万 USD | −419.8万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB47.38万0.00%108.2亿 USD0.44%US$204.26-1.08%
Fidelity Nasdaq Composite Index ETFONEQ5.61万—109.4亿 USD0.21%US$107.36-0.42%
Invesco Nasdaq Biotechnology ETFIBBQ1.17万0.01%1.12亿 USD0.19%US$34.2482-1.07%
ProShares Ultra Nasdaq BiotechnologyBIB6134.10.01%9320.36万 USD1.19%US$108.79-1.90%iShares Biotechnology ETFIBBFidelity Nasdaq Composite Index ETFONEQInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
